

Protecting and improving the nation's health

Analytical uses of patient data

National Cancer Registration and Analysis Service (NCRAS)



Audits

Benchmarking & routine monitoring

Campaigns

International review

Patient pathways

Peer-review

Service provision



Audits

National Lung Cancer Audit now uses **COSD** data





Apples and pears? A comparison of two sources of national lung cancer audit data in England

Aamir Khakwani¹, Ruth H. Jack², Sally Vernon³, Rosie Dickinson⁴, Natasha Wood³, Susan Harden⁵, Paul Beckett⁶, Ian Woolhouse⁷ and Richard B Hubbard¹

Affiliations: ¹University of Nottingham, Division of Epidemiology and Public Health, Nottingham, UK. ²Public Health England, National Cancer Registration and Analysis Services, Nottingham, UK, ³Public Health England, National Cancer Registration and Analysis Service, Cambridge, UK. ⁴Royal College of Physicians, National Lung Cancer Audit, London, UK. SCambridge University Hospital NHS Foundation Trust, Cambridge, UK. ⁶Derby Hospital NHS Foundation Trust, Division of Respiratory Medicine, Derby, UK. ⁷University Hospital Birmingham NHS Foundation Trust, Division of Respiratory Medicine, Birmingham, UK.

Correspondence: Aamir Khakwani, University of Nottingham, Division of Epidemiology and Public Health, Clinical Sciences Building, Nottingham City Hospital, Nottingham, NG5 1PB, UK. E-mail: aamir.khakwani@nottingham.ac.uk

ABSTRACT In 2014, the method of data collection from NHS trusts in England for the National Lung Cancer Audit (NLCA) was changed from a bespoke dataset called LUCADA (Lung Cancer Data). Under the new contract, data are submitted via the Cancer Outcome and Service Dataset (COSD) system and


"The findings suggest that the registry dataset coupled with COSD provides a richer dataset than LUCADA"

id treatment istic, K. e status and rith missing

...therapy and

ICADA data

COSD data. ompleteness





Benchmarking & routine monitoring

Range of tools available in the (semi-)public domain :

- Public Health Profiles (including GP profiles) all on <u>Fingertips</u>
- Longer Lives
- <u>CancerStats</u> (N3 network & login required)
- <u>CancerData (publically available)</u>
- NCRAS website
 - Topic and site specific reports/briefings
 - Guidance from ODR on obtaining data access
- Simulacrum coming soon!

Cancer Services

Demographics, Screening and Diagnostics						Two-Week Wait Referrals				
Overview	Compare indicators	9 Map	L Trends	E Compare areas	Area profiles	? Definitions	Download			
Area type GP							Benchmark England	~		
Area 🔹 🕨 P84009 - Ailsa Craig Medic					CCG Central Manchester					
	Se	earch not ava	ailable							
ndicator 4			or suspected b							

Indicator keywords

Q

Export chart as image Export table as image Lower Upper Area Value CI CI England NHS Central Manchester CCG P84009 - Ailsa Craig Me. P84053 - Ashcroft Surge... per 100,000 P84038 - Ashville Surge ... \circ P84068 - Chorlton Famil... P84652 - Corkland Road P84669 - Cornbrook Medi... P84026 - Dickenson Road... P84611 - Dr Chiu, Koh a ... P84037 - Dr Cunningham... P84028 - Gorton Medical... Y02890 - Hawthorn Mc P84016 - Levenshulme Me ... 20k 5k 10k 15k P84689 - Longsight Medi ... Effective population P84616 - Manchester Med.. P84050 - Mount Road Sur.. - England Y02960 - New Bank Healt ... - 95.0% Confidence P84676 - Oswald Road Me ... 1,121 1,487 99.8% Confidence P84644 - Parkside Surge...

Two-week wait referrals for suspected breast cancer (Number per 100,000 population) 2015/16 Crude rate - per 100,000

CancerData





he current Dashboard is phase 1	of this v	vork. See the background	tab below for mor	e details.				×
Reporting level	Provider • Rep		Reporting	rting geography Bradford Te		eaching Hospil 4s NHS Foundation Trust		
Tumour type	Tumours	T	Ambiti	ion/standard	I		Show Alliance	I
verview Trends Definitio	ons	Background					Key: Compared _* to England A worse similar no compa	
Patient experience								
verall experience of care 2015 rerage score (scale from 0 to 10)		Provision of information: CNS 2015 % of positive responses	given name of	Provision of in CNS 2015 % of positive re	nformation: easy	y to contact	Involvement in decisions: care treatment 2015 % of positive responses	e and
ighest Provider 8.64 owest Provider	10	79 Highest Provider Lowest Provider	99	77 Highest Provider Lowest Provider		98	67 Highest Provider 0 78.2 Lowest Provider	91
are transition: given contact after atient left hospital 2015		Care transition: support treatment 2015	from GP during	Overall interp and dignity 20	ersonal relation	is, respect		
of positive responses		% of positive responses		% of positive re				
r lighest Provider owest Provider	100	48 Highest Provider	75	73 Highest Provider		97		



PHE's cancer campaigns are those branded Be Clear on Cancer

- Led by Public Health England working in partnership with Department of Health, NHS England and Cancer Research UK
- Decisions are based on patient data to establish populations who may benefit the most and target advertising efficiently.
- Campaigns are evaluated using patient data to establish the effectiveness of the advertising
- Even a small change in the way data is recorded may affect the significance of results studied



1 in 3 women who get breast cancer are over 70, so don't assume you're past it.

Despite what people think, older women are more at risk and your chances actually increase with age. Anything unusual like a lump, a change to your nipples, akin or the shape of your breasts could be a sign of breast cancer, as tell your doctor straight away. Finding it early makes it more treatable and could save your life.





1 in 4 black men will get prostate cancer.

Prostate cancer often has no obvious symptoms. If you are a black man over 45 and want to discuss your personal risk of prostate cancer, visit your doctor.



Tell your doctor

1.2

Heartburn most days for three weeks or more? Tell your doctor.

Dr Jane Scott




ang to

NHS



Figure 1: Monthly number of urgent GP referrals for suspected breast cancer, breast symptom referrals and combined, from January 2012- August 2014, England, women aged 70+



The breast cancer awareness national campaign appears to have been successful in terms of raising public awareness of breast cancer in women over 70.



International review

International Cancer Benchmarking Partnership (ICBP):


- Spans across 22 jurisdictions, 8 countries and 3 continents.
- Phase 1 = Four cancers (breast, colorectal, lung, ovary)
- Five modules of study (3 complete):
 - International cancer survival benchmark
 - Examining public awareness, beliefs and attitudes to cancer
 - Role of primary care doctors and health systems in diagnosis
 - Measuring time intervals and pathways from symptoms to diagnosis and treatment
 - Impact of registry processes and comorbidities on short term outcomes


Without high quality data we cannot make valid inferences about differences in cancer outcomes between these geographies.






Barriers to symptomatic presentation: "Would any of these put you off going to the doctor with a symptom that might be serious?"







http://www.cancerresearchuk.org/sites/default/ files/icbp_showcase_report_web.pdf



International review


The ICBP has led to:


- Innovative methods and research tools to enable robust and unique international comparisons
- The first international comparisons of cancer survival and stage at diagnosis
- Cancer plans in England (and beyond)
- Innovations in diagnostic pathways in England
- Initiatives to improve access to diagnostics in England
- Projects to improve data completeness and availability in England





Representing patient pathways with NCRAS data – current developments


The challenge in interpreting pathway data is it's **volume** and **complexity**.
















Ensures scientific rigour

International peer-review by experts

Publications inform policy making, NICE guidelines, etc.

The Lancet (2016)

oa

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study

Michael Wallington", Emma B Saxon", Martine Bomb, Rebecca Smittenaar, Matthew Wickenden, Sean McPhail, Jem Rashbass, David Chao, John Dewar, Denis Talbot, Michael Peake, Timothy Perren, Charles Wilson, David Dodwell

Summary

"Our insights into the factors affecting risk of 30-day mortality will help treating clinicians and their patients predict the balance of harms and benefits associated with SACT."

non-small cell lung cancer (NSCLC) in our regression and trust-level analyses. 30-day mortality increased with age for both patients with breast cancer and patients with NSCLC treated with curative intent, and decreased with age for patients receiving palliative SACT (breast curative: odds ratio [OR] 1.085, 99% CI 1.040–1.132; p<0.0001; NSCLC curative: 1.045, 1.013–1.079; p=0.00033; breast palliative: 0.987, 0.977–0.996; p=0.00034; NSCLC palliative: 0.987, 0.976–0.998; p=0.0015). 30-day mortality was also significantly higher for patients receiving their first reported curative or palliative SACT versus those who received SACT previously (breast palliative: OR 2.326 99% CI 1.634–3.312; p<0.0001; NSCLC curative: 3.371, 1.554–7.316; p<0.0001; NSCLC palliative: 2.667, 2.109–3.373; p<0.0001), and for patients with worse general wellbeing (performance status 2–4) versus those who were generally well (breast curative: 6.057, 1.333–27.513; p=0.0021; breast palliative: 6.241, 4.180–9.319; p<0.0001; NSCLC palliative: 3.384, 2.276–5.032; p<0.0001). We identified trusts with mortality rates in excess of the 95% control limits; this included (M Peaks; Leeds Institute of Cancel Respiratory Medicine, Glenfield Hospital, Leidset, UK

Interpretation Our findings show that several factors affect the risk of early mortality of breast and lung cancer patients in England and that some groups are at a substantially increased risk of 30-day mortality. The identification of hospitals with significantly higher 30-day mortality rates should promote review of clinical decision making in these hospitals. Furthermore, our results highlight the importance of collecting routine data beyond clinical trials to better understand the factors placing patients at higher risk of 30-day mortality, and ultimately improve clinical decision making. Our insights into the factors affecting risk of 30-day mortality will help treating clinicians and their patients predict the balance of harms and benefits associated with SACT.

Funding Public Health England.

Copyright @ The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND license.

Hospital London, UK (D Chao FRCP); Department of Medical School, Dundee, UK () Dewar FRCR); University of Oxford Department of Oncology, Oxford, UK (Prof D Talbot PhD); University of Leicester, Department of **Respiratory Medicine**, Glenfield Hospital, Leicester, UK (M Peake); Leeds Institute of Pathology, St James's University Hospital, Leeds, UK (ProfT Perren MD); Oncology Centre, Addenbrooke's NHS Trust, Cambridge, UK (C Wilson MD); and Institute of Oncology, St James's Hospital, Leeds, UK (Prof D Dodwell MD) Correspondence to: Prof David Dodwell, Institute of Oncology, St James's Hospital, Londs LS9 7TE UK david.dodwell@nhs.net

The Lancet (2016)




Figure 3: Funnel plot of variation in risk-adjusted 30-day montality in patients with breast cancer given systemic anticancer therapy with palliative intent (by hospital trust

Each circle represents a separate hospital trust; blue and red circles represent outliers beyond the 95% and 99-8% confidence interval boundaries that are represented as grey lines. Red line shows national risk-adjusted 30-day mortality rate.



Routine metrics and bespoke analyses support service provision

Example analyses include:

- Radiotherapy activity across England
- Investigation of repeat diagnostic imaging across hospital trusts
- Inpatient bed use by cancer patients total and time trends
- Variations in days spent as a hospital inpatient
- Emergency visits in the last year of life

Repeat imaging in London: Trust Pathways for Chest x-rays for lung cancer



Subsequent image



Clinical Services Quality Measures are a series of metrics that are intended to allow for direct comparisons between services provided by hospitals

"Ofsted for the NHS"

CSQMs for stroke are already available on MyNHS.

The quality and completeness of the data feeds directly into the results.

Data sources include COSD, HES, CPES, SACT, RTDS etc.

The first cancer CSQMs will cover breast, colorectal and lung cancers.

Metrics are chosen in consultation with clinicians and patient groups.

All groups chose to have a metric on that reported on data quality and completeness.

What will they look like?



Service provision: CSQMs

Sort by distance	Overall Stroke Care Rating (Adjusted)	Number of patients admitted in one quarter	Change in performance from previous quarter	Team Key Indicator Level	Proportion of stroke cases included in SSNAP (Case ascertainment)	Completeness and timeliness of data (Audit compliance)	Name of stroke service
		\Leftrightarrow					
0	0	0	0	0	0	0	0
Salford Royal Salford Royal, Stott Lane, Salford, M6 8HD Tel: 0161 789 7373	Α	584	Improvement	Α	Α	A	Salford Royal Hospital
3.2 miles away							
Add to shortlist							
Stepping Hill Hospital Poplar Grove, Hazel Grove, Stockport, Cheshire, SK2 7JE Tel: 0161 483 1010	В	333	Decline	A	A	В	Stepping Hill Hospital
8.1 miles away							
Add to shortlist							
Fairfield General Hospital Fairfield General Hospital, Rochdale Old Road, Bury, Lancashire, BL9 7TD Tel: 0161 764 6081	A	322	No change	A	A	A	Fairfield General Hospital
8.4 miles away							
Add to shortlist							



This work uses data provided by patients and collected by the NHS as part of their care and support.

Presented by: Columbus Ohaeri (Columbus.ohaeri@phe.gov.uk)

For enquiries, contact

katherine.henson@phe.gov.uk